{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:51:37Z","timestamp":1784263897982,"version":"3.55.0"},"reference-count":51,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.5582\/bst.2025.01072","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T22:06:53Z","timestamp":1745878013000},"page":"296-308","source":"Crossref","is-referenced-by-count":1,"title":["Advancing precision medicine in immune checkpoint blockade for HIV\/AIDS: Current strategies and future directions"],"prefix":"10.5582","volume":"19","author":[{"given":"Xiangyi","family":"Tang","sequence":"first","affiliation":[{"name":"School of Public Health Bengbu Medical University, Bengbu, China."},{"name":"The Third People&apos;s Hospital of Shenzhen, National Clinical Research Center for Infectious Diseases and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Public Health Bengbu Medical University, Bengbu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiling","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health Bengbu Medical University, Bengbu, China."},{"name":"The Third People&apos;s Hospital of Shenzhen, National Clinical Research Center for Infectious Diseases and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibin","family":"Liao","sequence":"additional","affiliation":[{"name":"The Third People&apos;s Hospital of Shenzhen, National Clinical Research Center for Infectious Diseases and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Public Health Bengbu Medical University, Bengbu, China."},{"name":"The Third People&apos;s Hospital of Shenzhen, National Clinical Research Center for Infectious Diseases and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Liu XJ, McGoogan JM, Wu ZY. Human immunodeficiency virus\/acquired immunodeficiency syndrome prevalence, incidence, and mortality in China, 1990 to 2017: a secondary analysis of the Global Burden of Disease Study 2017 data. Chin Med J (Engl). 2021; 134:1175-1180.","DOI":"10.1097\/CM9.0000000000001447"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Abana CZ, Lamptey H, Bonney EY, Kyei GB. HIV cure strategies: which ones are appropriate for Africa? Cell Mol Life Sci. 2022; 79:400.","DOI":"10.1007\/s00018-022-04421-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wu X, Wu G, Ma P, <i>et al<\/i>. Immediate and long-term outcomes after treat-all among people living with HIV in China: an interrupted time series analysis. Infect Dis Poverty. 2023; 12:73.","DOI":"10.1186\/s40249-023-01119-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung&apos;u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR; International AIDS Society (IAS) Global Scientific Strategy working group. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. 2021; 27:2085-2098.","DOI":"10.1038\/s41591-021-01590-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Uldrick TS, Gon\u00e7alves PH, Abdul-Hay M, <i>et al<\/i>. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer \u2013 A Phase 1 Study. JAMA Oncol. 2019; 5:1332-1339.","DOI":"10.1001\/jamaoncol.2019.2244"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022; 21:28.","DOI":"10.1186\/s12943-021-01489-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Boyer Z, Palmer S. Targeting Immune Checkpoint Molecules to Eliminate Latent HIV. Front Immunol. 2018; 9:2339.","DOI":"10.3389\/fimmu.2018.02339"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. El Zarif T, Nassar AH, Adib E, <i>et al<\/i>. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the CATCH-IT Consortium. J Clin Oncol. 2023; 41:3712-3723.","DOI":"10.1200\/JCO.22.02459"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gay CL, Bosch RJ, McKhann A, <i>et al<\/i>. Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy. Open Forum Infect Dis. 2024; 11:ofad694.","DOI":"10.1093\/ofid\/ofad694"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Colston E, Grasela D, Gardiner D, Bucy RP, Vakkalagadda B, Korman AJ, Lowy I. An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. PLoS One. 2018; 13:e0198158.","DOI":"10.1371\/journal.pone.0198158"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gougis P, Jochum F, Abbar B, Dumas E, Bihan K, Lebrun-Vignes B, Moslehi J, Spano JP, Laas E, Hotton J, Reyal F, Hamy AS, Salem JE. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade \u2013 a worldwide perspective. EClinicalMedicine. 2024; 70:102536.","DOI":"10.1016\/j.eclinm.2024.102536"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, Pantaleo G. T-cell exhaustion in HIV infection. Immunol Rev. 2019; 292:149-163.","DOI":"10.1111\/imr.12823"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Baldanzi G. Immune Checkpoint Receptors Signaling in T Cells. Int J Mol Sci. 2022; 23:3529.","DOI":"10.3390\/ijms23073529"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Brunet-Ratnasingham E, Morou A, Dub\u00e9 M, Niessl J, Baxter AE, Tastet O, Brassard N, Ortega-Delgado G, Charlebois R, Freeman GJ, Tremblay C, Routy JP, Kaufmann DE. Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function. EBioMedicine. 2022; 84:104254.","DOI":"10.1016\/j.ebiom.2022.104254"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, Pavlik DF, Rodriguez-Garcia M, Pereyra F, Freeman GJ, Kavanagh DG, Kaufmann DE. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011; 118:965-974.","DOI":"10.1182\/blood-2010-12-328070"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gubser C, Chiu C, Lewin SR, Rasmussen TA. Immune checkpoint blockade in HIV. EBioMedicine. 2022; 76:103840.","DOI":"10.1016\/j.ebiom.2022.103840"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gay CL, Bosch RJ, Ritz J, <i>et al<\/i>. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. J Infect Dis. 2017; 215:1725-1733.","DOI":"10.1093\/infdis\/jix191"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Delyon J, Biard L, Renaud M, <i>et al<\/i>. PD-1 blockade with pembrolizumab in classic or endemic Kaposi\u2019s sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2022; 23:491-500.","DOI":"10.1016\/S1470-2045(22)00097-3"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gonzalez-Cao M, Mor\u00e1n T, Dalmau J, <i>et al<\/i>. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study. JAMA Oncol. 2020; 6:1063-1067.","DOI":"10.1001\/jamaoncol.2020.0465"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sinha N, Sinha S, Valero C, Sch\u00e4ffer AA, Aldape K, Litchfield K, Chan TA, Morris LGT, Ruppin E. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. Cancer Res. 2022; 82:2076-2083.","DOI":"10.1158\/0008-5472.CAN-21-2542"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Deng H, Zhao Y, Cai X, Chen H, Cheng B, Zhong R, Li F, Xiong S, Li J, Liu J, He J, Liang W. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022; 170:103582.","DOI":"10.1016\/j.critrevonc.2022.103582"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184:5309-5537.","DOI":"10.1016\/j.cell.2021.09.020"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N, Pundole X, Aldrich JD, Carey P, Khan M, Geng Y, Pratt G, Suarez-Almazor ME. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease. Eur J Cancer. 2024; 207:114148.","DOI":"10.1016\/j.ejca.2024.114148"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Harper J, Gordon S, Chan CN, <i>et al<\/i>. CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption. Nat Med. 2020; 26:519-528.","DOI":"10.1038\/s41591-020-0782-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Rasmussen TA, Rajdev L, Rhodes A, <i>et al<\/i>. Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clin Infect Dis. 2021; 73:e1973-e1981.","DOI":"10.1093\/cid\/ciaa1530"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Rahman SA, Yagnik B, Bally AP, Morrow KN, Wang S, Vanderford TH, Freeman GJ, Ahmed R, Amara RR. PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue. Sci Immunol. 2021; 6:eabh3034.","DOI":"10.1126\/sciimmunol.abh3034"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Wu C, He Y, Zhao J, Luo K, Wen Z, Zhang Y, Li M, Cui Y, Liu Z, Wang C, Han Z, Li G, Feng F, Li P, Chen L, Sun C. Exacerbated AIDS Progression by PD-1 Blockade during Therapeutic Vaccination in Chronically Simian Immunodeficiency Virus-Infected Rhesus Macaques after Interruption of Antiretroviral Therapy. J Virol. 2022; 96:e0178521.","DOI":"10.1128\/jvi.01785-21"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wu L, Zheng Z, Xun J, <i>et al<\/i>. Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a &quot;shock and kill&quot; strategy for ART-free virological control: a phase II single-arm study. Signal Transduct Target Ther. 2024; 9:231.","DOI":"10.1038\/s41392-024-01943-9"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Lu L, Wang J, Yang Q, Xie X, Huang Y. The role of CD38 in HIV infection. AIDS Res Ther. 2021; 18:11.","DOI":"10.1186\/s12981-021-00330-6"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Li W, Liang L, Liao Q, Li Y, Zhou Y CD38: An important regulator of T cell function. Biomed Pharmacother. 2022; 153:113395.","DOI":"10.1016\/j.biopha.2022.113395"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, Nanni P, Lollini PL, Palladini A. IFN-\u03b3 and CD38 in Hyperprogressive Cancer Development. Cancers (Basel). 2021; 13:309.","DOI":"10.3390\/cancers13020309"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Spreafico A, Janku F, Rodon JA, <i>et al<\/i>. A phase I study of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3). Ann Oncol. 2019; 30(Suppl 5):v488-v489.","DOI":"10.1093\/annonc\/mdz253.023"},{"key":"33","unstructured":"33. U.S. National Library of Medicine. A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors. NCT04911894. https:\/\/clinicaltrials.gov\/study\/NCT04911894 (accessed August 6, 2024)."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Bekerman E, Hesselgesser J, Carr B, Nagel M, Hung M, Wang A, Stapleton L, von Gegerfelt A, Elyard HA, Lifson JD, Geleziunas R. PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy. Antimicrob Agents Chemother. 2019; 63:e01163-19.","DOI":"10.1128\/AAC.01163-19"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Lau JSY, McMahon JH, Gubser C, Solomon A, Chiu CYH, Dantanarayana A, Chea S, Tennakoon S, Zerbato JM, Garlick J, Morcilla V, Palmer S, Lewin SR, Rasmussen TA. The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. AIDS. 2021; 35:1631-1636.","DOI":"10.1097\/QAD.0000000000002919"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Dhodapkar KM, Duffy A, Dhodapkar MV. Role of B cells in immune-related adverse events following checkpoint blockade. Immunol Rev. 2023; 318:89-95.","DOI":"10.1111\/imr.13238"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Cariou PL, Pobel C, Michot JM, Danlos FX, Besse B, Carbonnel F, Mariette X, Marabelle A, Messayke S, Robert C, Routier E, No\u00ebl N, Lambotte O. Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers. Eur J Cancer. 2024; 204:114065.","DOI":"10.1016\/j.ejca.2024.114065"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Qiu J, Cheng Z, Jiang Z, Gan L, Zhang Z, Xie Z. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment. Int J Mol Sci. 2024; 25:5490.","DOI":"10.3390\/ijms25105490"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Benito JM, Restrepo C, Garc\u00eda-Foncillas J, Rall\u00f3n N. Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV. Front Immunol. 2023; 14:1270881.","DOI":"10.3389\/fimmu.2023.1270881"},{"key":"40","unstructured":"40. U.S. National Library of Medicine. Treatment of PD-1 Inhibitor in AIDS-associated PML (TPAP). NCT04091932. <i>https:\/\/clinicaltrials.gov\/study\/NCT04091932<\/i> (accessed August 6, 2024)."},{"key":"41","unstructured":"41. U.S. National Library of Medicine. A Single Dose of Pembrolizumab in HIV-Infected People. NCT03367754. <i>https:\/\/clinicaltrials.gov\/study\/NCT03367754<\/i> (accessed August 6, 2024)."},{"key":"42","unstructured":"42. U.S. National Library of Medicine. Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV. NCT04514484. <i>https:\/\/clinicaltrials.gov\/study\/NCT04514484<\/i> (accessed August 6, 2024)."},{"key":"43","unstructured":"43. U.S. National Library of Medicine. Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy (NIVO-LD). NCT05187429. <i>https:\/\/clinicaltrials.gov\/study\/NCT05187429<\/i> (accessed June 16, 2024)."},{"key":"44","unstructured":"44. U.S. National Library of Medicine. Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma. NCT03316274. <i>https:\/\/clinicaltrials.gov\/study\/NCT03316274<\/i> (accessed June 16, 2024)."},{"key":"45","unstructured":"45. U.S. National Library of Medicine. Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer. NCT04929028. <i>https:\/\/clinicaltrials.gov\/study\/NCT04929028<\/i> (accessed August 6, 2024)."},{"key":"46","unstructured":"46. U.S. National Library of Medicine. Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV. NCT05330143. <i>https:\/\/clinicaltrials.gov\/study\/NCT05330143<\/i> (accessed August 6, 2024)."},{"key":"47","unstructured":"47. U.S. National Library of Medicine. Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer. NCT04499053. <i>https:\/\/clinicaltrials.gov\/study\/NCT04499053<\/i> (accessed June 16, 2024)."},{"key":"48","unstructured":"48. U.S. National Library of Medicine. Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma (STARKAP). NCT05646082. <i>https:\/\/clinicaltrials.gov\/study\/NCT05646082<\/i> (accessed June 16, 2024)."},{"key":"49","unstructured":"49. U.S. National Library of Medicine. ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint). NCT03354936. <i>https:\/\/clinicaltrials.gov\/study\/NCT03354936<\/i> (accessed June 16, 2024)."},{"key":"50","unstructured":"50. U.S. National Library of Medicine. Nivolumab\/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR). NCT05597800. <i>https:\/\/clinicaltrials.gov\/study\/NCT05597800<\/i> (accessed June 16, 2024)."},{"key":"51","unstructured":"51. U.S. National Library of Medicine. Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery. NCT02408861. <i>https:\/\/clinicaltrials.gov\/study\/NCT02408861<\/i> (accessed June 16, 2024)."}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/3\/19_2025.01072\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:32:01Z","timestamp":1751689921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/3\/19_2025.01072\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2025.01072","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"2025.01072"}}